Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction

Circulation Research

Volumn 97, Issue 7, 2005, Pages 707-715

  Giebing, Günter ^a   Tolle, Markus ^a   Jürgensen, Jana ^a   Eichhorst, Jenny ^b   Furkert, Jens ^b   Beyermann, Michael ^b   Neuschäfer Rube, Frank ^c   Rosenthal, Walter ^b   Zidek, Walter ^a   Van Der Giet, Markus ^a   Oksche, Alexander ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

Author keywords

Internalization; Recycling; Urotensin II; Urotensin receptor; Vascular tone

Indexed keywords

ARRESTIN 2; ARRESTIN 3; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; RECEPTOR PROTEIN; RETINA S ANTIGEN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN RECEPTOR;

ANIMAL CELL; ARTICLE; BLOOD VESSEL TONE; CELL MEMBRANE; CELL STRAIN HEK293; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; ENDOCYTOSIS; ENDOSOME; FIBROBLAST; HALF LIFE TIME; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; RAT; VASCULAR RING; VASOCONSTRICTION;

ANIMALS; ARRESTINS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSOMES; HUMANS; MICE; RATS; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS; VASOCONSTRICTION;

EID: 26244465123     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000184670.58688.9F     Document Type: Article

References (41)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282-286.
2. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med, 2000;10:229-237.
3. Douglas SA, Ohlstein EH. Urotensin Receptors. London, UK: IUPHAR Media; 2000.
4. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J, Aiyar NV. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol. 2002;136:9-22.
5. Saetrum Opgaard O, Nothacker H, Ehlert FJ, Krause DN. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol. 2000;406:265-271.
6. Tasaki K, Hori M, Ozaki H, Karaki H, Wakabayashi I. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci. 2004;94:376-383.
7. Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002;438:159-170.
8. Douglas SA, Sulpiiio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131:1262-1274.
9. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol. 2001;132:1625-1629.
10. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359:1990-1997.
11. Shenouda A, Douglas SA, Ohlstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem. 2002;50:885-889.
12. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol. 2000;131:441-446.
13. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol. 2002;135:25-27.
14. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:H925-H928.
15. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation. 2004;109:1212-1214.
16. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol. 2002;54:617-621.
17. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res. 2002;53:341-347.
18. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, McMurray J. Effects of urotensin II in human arteries and veins of varying caliber. Circulation. 2001;103:1378-1381.
19. Douglas SA. Human urotensin-II as a novel cardiovascular target: "heart" of the matter or simply a fishy "tail"? Curr Opin Pharmacol. 2003;3:159-167.
20. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Muller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P. Pharmacology of the urotensin-II receptor antagonist ACT- 058362: first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther. 2004;311:204-212.
21. Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D. Effects of human urotensin II in isolated vessels of various species: comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:141-149.
22. Marsault R, Feolde E, Frelin C. Receptor externalization determines sustained contractile responses to endothelin-1 in the rat aorta. Am J Physiol. 1993;264:C687-C693.
23. Oksche A, Boese G, Horstmeyer A, Furkert J, Beyermann M, Bienert M, Rosenthal W. Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol. 2000;57:1104-1113.
24. Grantcharova E, Furkert J, Reusch HP, Krell HW, Papsdorf G, Beyermann M, Schulein R, Rosenthal W, Oksche A. The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process. J Biol Chem. 2002;277:43933-43941.
25. Neuschafer-Rube F, Hermosilla R, Kuna M, Pathe-Neuschafer-Rube A, Schulein R, Puschel GP. A Ser/Thr cluster within the C-terminal domain of the rat prostaglandin receptor EP3alpha is essential for agonist-induced phosphorylation, desensitization and internalization. Br J Pharmacol. 2005;145:1132-1142.
26. Oksche A, Dehe M, Schulein R, Wiesner B, Rosenthal W. Folding and cell surface expression of the vasopressin V2 receptor: requirement of the intracellular C-terminus. FEBS Lett. 1998;424:57-62.
27. Wiesner B, Beyermann M, Oksche A. Live cell imaging of G protein-coupled receptors. Methods Mole Biol. 2000;306:173-179.
28. Tepel M, Bachmann J, Schluter H, Zidek W. Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin-II-induced changes of calcium in vascular smooth muscle cells. J Vasc Res. 1996;33:132-138.
29. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem. 2002;45:1799-1805.
30. Grieco P, Rovero P, Novellino E. Recent structure-activity studies of the peptide hormone urotensin-II, a potent vasoconstrictor. Curr Med Chem. 2004;11:969-979.
31. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002;115:455-465.
32. Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Menard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 1996;271:363-366.
33. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, beta arrestin 1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem. 2000;275:17201-17210.
34. Lee KB, Pals-Rylaarsdam R, Benovic JL, Hosey MM. Arrestin-independent internalization of the m1, m3, and m4 subtypes of muscarinic cholinergic receptors. J Biol Chem. 1998;273:12967-12972.
35. Smyth EM, Austin SC, Reilly MP, FitzGerald GA. Internalization and sequestration of the human prostacyclin receptor. J Biol Chem. 2000;275:32037-32045.
36. Paing MM, Stutts AB, Kohout TA, Lefkowitz RJ, Trejo J. Beta-arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation. J Biol Chem. 2002;277:1292-1300.
37. Onan D. Cardiovascular and Regulatory Aspects of the Urotensin-II Receptor [thesis], Prahran, Australia: Molecular Endocrinology Laboratory, Baker Heart Research Institute, Monash University; 2004.
38. Proulx CD, Simaan M, Escher E, Laporte SA, Guillemette G, Leduc R. Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization. Biochem J. 2005;385:115-123.
39. Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP). Pharmacol Ther. 2004;103:203-221.
40. Aiyar N, Johns DG, Ao Z, Disa J, Behm DJ, Foley JJ, Buckley PT, Sarau HM, van-der-Keyl HK, Elshourbagy NA, Douglas SA. Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). Biochem Pharmacol. 2005;69:1069-1079.
41. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckies SP, Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol. 1999;1:383-385.